Explore the categories so you can find more about your search.
Categorie > Bipolar
Alexza Initiates Second Phase 3 Clinical Trial For AZ-004 (Staccato(R) Loxapine)
Categorie : BipolarAlexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has initiated its second Phase 3 clinical trial with AZ-004 (Staccato(R) loxapine). AZ-004 is an inhalation product candidate being developed for the treatment of acute agitation in patients with schizophrenia or bipolar disorde ...
read more 
Sat Jul 2008
Partially Shared Genetic Profile Between Schizophrenia And Bipolar Disorder Discovered
Categorie : BipolarBoth schizophrenia and bipolar disorder can be disabling conditions, and both present clinically with significant mood and psychotic symptoms. These two illnesses also share genetic variants that might be involved in the predisposition to both disorders. ...
read more Sat Jul 2008
Improving Traditional Psychiatric Diagnoses With Genetics
Categorie : BipolarPsychiatry has begun the laborious effort of preparing the DSM-V, the new iteration of its diagnostic manual. In so doing, it once again wrestles with the task set by Carl Linnaeus, to "cleave nature at its joints." However, these "joints," the boundaries between psychiatric disorders, such as that ...
read more Sat Jul 2008
Astrazeneca Sponsors Service User- Involvement In Research Into Recovery For Mental Health
Categorie : BipolarTwo leading mental health charities, Rethink and MDF The BiPolar Organisation today announced the start of a new partnership with and project sponsored by AstraZeneca. It comprises of experiential research to identify what hinders and helps achieve recovery and aims to help to put recovery at ...
read more Sat Jul 2008
The ECNP Consensus Statement On Bipolar Depression
Categorie : BipolarBipolar disorder is one of the most complex and challenging mental disorder in the spectrum. Bipolar disorder is typically associated with considerable acute and longterm treatment needs and may be associated in the course of illness with times of tremendous social burden for both the individual and ...
read more Tue Jul 2008
New Scholarship For Leaders Of Bipolar Lives
Categorie : BipolarWhat do you do when you want to let the bipolar community know about scholarships for people with bipolar disorder, but soon discover that support for bipolar students is still far too rare? Why donate a scholarship yourself of course. The Bipolar Lives Scholarship is a new scholarship, created w ...
read more Tue Jul 2008
Relapse Time Prolonged In Clinically Stable Patients With Bipolar I Disorder Treated With Quetiapine As Adjunct Therapy To Mood Stabilisers
Categorie : BipolarAstraZeneca announced the online publication of long-term SEROQUEL® (quetiapine fumarate) clinical trial data in the Journal of Affective Disorders. Results show that SEROQUEL in combination with lithium or divalproex significantly increased the time to recurrence of any mood event in patients with ...
read more Sat Jul 2008
Benefits Of Omega 3s Still Unclear For Bipolar Disorder
Categorie : BipolarDespite intriguing findings that omega 3 fatty acid supplements could alleviate depression symptoms, there is still not enough evidence to say whether omega 3s are useful treatments for people with bipolar disorder, according to a review of recent studies. ...
read more Thu Jun 2008
Perceptual Switch Rates With Ambiguous Structure-from-motion Figures In Bipolar Disorder
Categorie : BipolarMost people believe that the way we see things is affected by how we feel emotionally. Does our mood really change what we see or do individuals with certain genetic traits always tend to see things differently, regardless of their mood? Earlier research suggested that people with bipolar mood disor ...
read more Thu Jun 2008
Overview Of Asenapine Data From Olympia Trial Program Presented At American Psychiatric Association Annual Meeting
Categorie : BipolarSchering-Plough Corporation (NYSE: SGP) announced that an overview of asenapine clinical trials from the Olympia program was presented at the 161st Annual Meeting of the American Psychiatric Association in Washington, D.C., May 3-8. Data from the studies, involving patients with bipolar I disorder ...
read more Thu Jun 2008
Problems Identified With Diagnosis Of Bipolar Disorder
Categorie : BipolarA new study by Rhode Island Hospital and Brown University researchers reports that fewer than half the patients previously diagnosed with bipolar disorder received a diagnosis of bipolar disorder based on a comprehensive, psychiatric diagnostic interview - -the Structured Clinical Interview for DSM- ...
read more Thu Jun 2008
Report Confirms Increased Risk Of Smoking, Substance Abuse In Bipolar Adolescents
Categorie : BipolarA study from the Massachusetts General Hospital (MGH) supports previous reports that adolescents with bipolar disorder are at increased risk for smoking and substance abuse. The article appearing in the June Drug and Alcohol Dependence - describing the largest such investigation to date and the firs ...
read more Thu Jun 2008
NARSAD Researchers Identify Specific Genes And Family Traits Linked To Schizophrenia, Bipolar Disorder And Depression
Categorie : BipolarNew findings from research supported by NARSAD, the world's leading charity dedicated to mental health research, and conducted by Harvard-affiliated scientists are providing important clues into how genes work to impair various aspects of attention, memory and perception -- the behaviors associated ...
read more Thu Jun 2008
ABILIFY(R) (aripiprazole) Receives Expanded Indications For Maintenance Treatment In Pediatric Patients With Bipolar Disorder And Schizophrenia
Categorie : BipolarOtsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced that ABILIFY® (aripiprazole) received expanded indications in Bipolar I Disorder and Schizophrenia. ABILIFY is now indicated for maintenance treatment of manic and mixed episodes associated with Bipolar I Disorder ...
read more Thu Jun 2008
FDA Approves Astrazeneca's Seroquel For Maintenance Treatment In Bipolar Disorder
Categorie : BipolarAstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL® (quetiapine fumarate) for the maintenance treatment of patients with bipolar I disorder, as adjunct to lithium or divalproex. SEROQUEL is approved by the FDA for the treatment of schizophrenia, and is also ...
read more Thu Jun 2008
Repligen Announces Plans To Initiate A Phase 2b Trial For RG2417 In Bipolar Disorder
Categorie : BipolarRepligen Corporation (Nasdaq: RGEN) announced that based on feedback from the Food and Drug Administration, the Company plans to initiate a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar disorder later this year. This will be a multi-center, parallel ar ...
read more Thu Jun 2008
Antidepressants Alone: Not For Bipolar Depression
Categorie : BipolarPsychiatrists have cautioned against the use of antidepressants alone in people with bipolar disorders, saying they could worsen a patient's condition by causing a destabilisation in mood. ...
read more Thu Jun 2008
Alcohol Dependence May Respond To Aripiprazole, Treatment For Bipolar Disorder And Schizophrenia.
Categorie : Bipolar* Aripiprazole is currently approved to treat bipolar disorder as well as schizophrenia. * A new study has found that it significantly and dose-dependently increases the sedative effects of alcohol and, to a lesser degree, decreases the euphoric effects of alcohol. * Future research will n ...
read more Sat Apr 2008
Famous Bipolar People Contest Raises Awareness, Encourages Research
Categorie : BipolarFamous bipolar people include some of the world's foremost musicians, actors, writers, composers and scientists. A new contest launched on YouTube uses the current interest in bipolar celebrities to raise awareness about bipolar disorder. The Famous Bipolar People Contest encourages research and ref ...
read more Sat Apr 2008
Supplemental New Drug Application For RISPERDAL(R) CONSTA(R) Submitted To The FDA For The Treatment Of Frequently Relapsing Bipolar Disorder
Categorie : BipolarAlkermes, Inc. (NASDAQ: ALKS) announced that its partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), submitted a Supplemental New Drug Application (sNDA) for RISPERDAL® CONSTA® [(risperidone) Long-Acting Injection] to the U.S. Food and Drug Administration (FDA) seeking ...
read more Sat Apr 2008
Custom Search
